{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=7", "query": { "intervention": "antibody-drug conjugate", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 499, "total_pages": 50, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T17:26:58.448Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05408845", "title": "Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Salivary Gland Carcinoma", "Recurrent Salivary Gland Carcinoma", "Stage III Major Salivary Gland Cancer AJCC v8", "Stage IV Major Salivary Gland Cancer AJCC v8", "Unresectable Salivary Gland Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2023-03-03", "completion_date": "2032-07-31", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-14T17:26:58.448Z", "location_count": 152, "location_summary": "Birmingham, Alabama • Duarte, California • Dublin, California + 127 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05408845" }, { "nct_id": "NCT07444814", "title": "Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "Ovarian Cancer", "Ovarian Cancer Metastatic", "Ovarian Cancer Metastatic Recurrent", "Non-squamous EGFR Wt NSCLC", "Platinum Resistant Ovarian Cancer", "PROC" ], "interventions": [ { "name": "HWK-007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Whitehawk Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2025-12-19", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-14T17:26:58.448Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07444814" }, { "nct_id": "NCT05320588", "title": "A Study in Patients With Advanced Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Advanced Solid Tumor", "Cancer", "Oncology" ], "interventions": [ { "name": "BIO-106", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BiOneCure Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2022-03-25", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-10-14T17:26:58.448Z", "location_count": 3, "location_summary": "Austin, Texas • Houston, Texas • Fairfax, Virginia", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05320588" }, { "nct_id": "NCT04686305", "title": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "T-DXd", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Volrustomig", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 304, "start_date": "2021-03-09", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-14T17:26:58.448Z", "location_count": 13, "location_summary": "Duarte, California • Newport Beach, California • Orange, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04686305" }, { "nct_id": "NCT04293562", "title": "A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Asparaginase Erwinia chrysanthemi", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexrazoxane Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Gilteritinib Fumarate", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 1400, "start_date": "2020-07-21", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-14T17:26:58.448Z", "location_count": 186, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04293562" }, { "nct_id": "NCT04795869", "title": "Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Angioimmunoblastic T-Cell Lymphoma", "Recurrent Enteropathy-Associated T-Cell Lymphoma", "Recurrent Follicular T-Cell Lymphoma", "Recurrent Hepatosplenic T-Cell Lymphoma", "Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma", "Refractory Angioimmunoblastic T-Cell Lymphoma", "Refractory Enteropathy-Associated T-Cell Lymphoma", "Refractory Follicular T-Cell Lymphoma", "Refractory Hepatosplenic T-Cell Lymphoma", "Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-03-01", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-10-14T17:26:58.448Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04795869" }, { "nct_id": "NCT02606305", "title": "Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Mirvetuximab soravtansine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 264, "start_date": "2016-03-02", "completion_date": "2021-03-12", "has_results": true, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-10-14T17:26:58.448Z", "location_count": 7, "location_summary": "Los Angeles, California • Boston, Massachusetts • Reno, Nevada + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Reno", "state": "Nevada" }, { "city": "Hilliard", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02606305" }, { "nct_id": "NCT03013933", "title": "Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Pharmacokinetic Study", "type": "OTHER" }, { "name": "Verapamil", "type": "DRUG" }, { "name": "Verapamil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 29, "start_date": "2017-05-03", "completion_date": "2022-05-24", "has_results": false, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-10-14T17:26:58.448Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013933" }, { "nct_id": "NCT05039073", "title": "Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Classic Hodgkin Lymphoma", "Refractory Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 46, "start_date": "2022-05-02", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-14T17:26:58.448Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039073" }, { "nct_id": "NCT05041257", "title": "Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Mirvetuximab soravtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 79, "start_date": "2021-10-19", "completion_date": "2024-12-12", "has_results": true, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-14T17:26:58.448Z", "location_count": 11, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Covington", "state": "Louisiana" }, { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05041257" } ] }